Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines

✍ Scribed by Jianghong Wu; Haruhiko Suzuki; Yan-Wen Zhou; Wei Liu; Motoi Yoshihara; Masashi Kato; Anwarul A. Akhand; Akemi Hayakawa; Kei Takeuchi; Khaled Hossain; Mio Kurosawa; Izumi Nakashima

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 292 KB
• Volume: 82
• Category: Article
• ISSN: 0730-2312
• DOI: 10.1002/jcb.1155

✦ Synopsis

Abstract

Cepharanthine (CEP) is a known membrane stabilizer that has been widely used in Japan for the treatment of several disorders such as anticancer therapy‐provoked leukopenia. We here report that apoptosis was induced by low concentrations (1–5 μM) of CEP in a human leukemia T cell line, Jurkat, and by slightly higher concentrations (5–10 μM) in a human chronic myelogenous leukemia (CML) cell line K562, which expresses a p210 antiapoptotic Bcr‐Abl fusion protein. Induction of apoptosis was confirmed in both Jurkat and K562 cells by DNA fragmentation and typical apoptotic nuclear change, which were preceded by disruption of mitochondrial membrane potential and were induced through a Fas‐independent pathway. CEP treatment induced activation of caspase‐9 and ‐3 accompanied by cleavage of PARP, Bid, lamin B~1~, and DFF45/ICAD in both Jurkat and K562 cells, whereas caspase‐8 activation and Akt cleavage were observed only in Jurkat cells. The CEP‐induced apoptosis was completely blocked by zVAD‐fmk, a broad caspase inhibitor. Interestingly, CEP treatment induced remarkable degradation of the Bcr‐Abl protein in K562 cells, and this degradation was prevented partially by zVAD‐fmk. When used in combination with a nontoxic concentration of herbimycin A, lower concentrations (2–5 μM) of CEP induced obvious apoptosis in K562 cells with rapid degradation or decrease in the amount of Bcr‐Abl and Akt proteins. Our results suggest that CEP, which does not have bone marrow toxicity, may possess therapeutic potential against human leukemias, including CML, which is resistant to anticancer drugs and radiotherapy. J. Cell. Biochem. 82: 200–214, 2001. © 2001 Wiley‐Liss, Inc.